The European Medicines Agency publishes its Brexit business continuity plan
- Published: Wednesday, 18 October 2017 11:59
The European Medicines Agency (EMA) has made its Brexit Preparedness Business Continuity Plan public. The plan aims to safeguard continuity of EMA’s operations to protect public health while the Agency prepares for its relocation to a new host city and the departure of the United Kingdom from the European Union.
The Brexit Preparedness Business Continuity Plan was presented to the EMA Management Board meeting in October 2017 and will be continuously reviewed and adapted as necessary.
The key aim of the business continuity plan is to ensure that the necessary human resources are available to work on EMA preparedness, and subsequently that activities with the highest priority will continue to operate at a 'business as usual' level, without interruption and to the same high standards.